Internal Medicine, Hematology & Oncology · Mineola, NY
NPI
1366495509
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
200 Old Country Rd, Suite 450
Mineola, NY, 11501
Phone (516) 663-9500
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
228,662 services
Medicare patients, 2024
1,471
Average age 76
Drug cost, 2024
$5.6M
1,207 prescriptions
Company payments, 2025
$24.98
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harry Staszewski was code J1439 (injection, ferric carboxymaltose, 1 mg), 73,500 times for 80 patients. In total Harry Staszewski billed 228,662 services in 250 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-01-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 73,500 | 80 | $0.87 | $64K |
| J0896 Injection, luspatercept-aamt, 0.25 mg | Office | 18,684 | 11 | $31.66 | $592K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 17,700 | 21 | $2.34 | $41K |
| J1756 Injection, iron sucrose, 1 mg | Office | 12,201 | 35 | $0.17 | $2,112 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,400 | 16 | $44.70 | $420K |
| J0897 Injection, denosumab, 1 mg | Office | 3,900 | 28 | $20.73 | $81K |
| 36415 Venipuncture Blood Collection | Office | 2,994 | 1,204 | $8.63 | $26K |
| 85025 Blood Count | Office | 2,911 | 1,107 | $7.59 | $22K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,711 | 85 | $0.09 | $239 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,160 | 11 | $37.20 | $80K |
| 80053 Clinical Chemistry | Office | 2,135 | 965 | $10.30 | $22K |
| 88185 Surgical Pathology Examination | Office | 1,472 | 59 | $21.69 | $32K |
| 99214 Office E&M - Established | Office | 1,197 | 648 | $107.50 | $129K |
| 83615 Clinical Chemistry | Office | 1,161 | 590 | $5.90 | $6,851 |
| 82784 Immunoassay | Office | 1,158 | 202 | $9.11 | $11K |
By year: 2022 $1.8M for 134,668 services; 2023 $2.1M for 163,940 services; 2024 $3.2M for 228,662 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,994 | 1,204 | $8.63 | $26K |
| 85025 Blood Count | 2,911 | 1,107 | $7.59 | $22K |
| 80053 Clinical Chemistry | 2,135 | 965 | $10.30 | $22K |
| 88185 Surgical Pathology Examination | 1,472 | 59 | $21.69 | $32K |
| 83615 Clinical Chemistry | 1,161 | 590 | $5.90 | $6,851 |
| 82784 Immunoassay | 1,158 | 202 | $9.11 | $11K |
| 84100 Clinical Chemistry | 1,034 | 552 | $4.64 | $4,793 |
| 82728 Clinical Chemistry | 999 | 555 | $13.35 | $13K |
| 83540 Clinical Chemistry | 968 | 531 | $6.34 | $6,133 |
| 83735 Clinical Chemistry | 947 | 487 | $6.55 | $6,204 |
Medicare prescription drug claims, 2024
In 2024, the drug Harry Staszewski prescribed most often to Medicare patients was Anastrozole, with 99 prescriptions and refills. In total Harry Staszewski wrote 1,207 Medicare prescriptions that cost $5.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 99 | 231 | 28 | $1,708 |
| Aranesp Darbepoetin Alfa In Polysorbat | 96 | 96 | 21 | $298K |
| Revlimid Lenalidomide | 62 | 62 | Under 11 | $980K |
| Hydroxyurea Generic | 62 | 109 | 12 | $835 |
| Eliquis Apixaban | 48 | 57 | 11 | $34K |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 37 | 37 | Under 11 | $189K |
| Acyclovir Generic | 32 | 66 | Under 11 | $583 |
| Prednisone Generic | 32 | 34 | Under 11 | $212 |
| Xarelto Rivaroxaban | 32 | 48 | Under 11 | $27K |
| Ibrance Palbociclib | 30 | 35 | Under 11 | $563K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 29 | 29 | Under 11 | $353K |
| Jakafi Ruxolitinib Phosphate | 22 | 22 | Under 11 | $375K |
| Procrit Epoetin Alfa | 20 | 20 | Under 11 | $37K |
| Lenalidomide Generic | 20 | 20 | Under 11 | $217K |
| Allopurinol Generic | 20 | 34 | Under 11 | $43.56 |
Brand drugs: 630 claims; generic drugs: 577 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harry Staszewski $24.98 ($24.98 in general payments such as food, travel and fees) from 1 company. The largest payer was Kyowa Kirin, Inc. with $24.98.
| Company | Payments | Amount |
|---|---|---|
| Kyowa Kirin, Inc. 4151.T | 1 | $24.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.